Vertex Inks Another Orkambi Reimbursement Deal After France Says Yes

The reimbursement deal will allow cystic fibrosis patients as young as two years of age to access Orkambi in France for the first time.

French flag
Vertex has secured a reimbursement deal in France for Orkambi • Source: Shutterstock

Vertex Pharmaceuticals has secured a reimbursement deal in France for Orkambi (lumacaftor/ivacaftor), the cystic fibrosis drug that England’s National Health Service last month agreed to reimburse after more than three years of disagreement and stalemate in negotiations with the company.

France’s drug pricing body, the Comité économique des produits de santé (CEPS), has approved national reimbursement of Orkambi for CF...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Market Access

More from Pink Sheet